VERACYTE, INC. (NASDAQ:VCYT) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
Stockholders of Veracyte, Inc., held on June 6, 2017:
|
1.
|
The following Class I Directors were elected to serve until
the 2020 Annual Meeting of Stockholders or until their successors are duly elected and qualified: |
|
|
For
|
|
Withheld
|
Broker Non-Votes
|
||||
|
Bonnie H. Anderson
|
29,748,620
|
|
487,396
|
1,974,587
|
||||
|
Robert S. Epstein
|
28,366,435
|
|
1,869,581
|
|
1,974,587
|
|||
|
Evan Jones
|
23,034,675
|
|
|
7,201,341
|
|
|
1,974,587
|
|
|
2.
|
The ratification of the appointment of Ernst Young LLP as the
Company’s independent registered public accounting firm for 2017 was approved: |
|
For
|
|
Against
|
|
Abstain
|
|||
|
32,207,194
|
|
|
3,404
|
|
|
|
About VERACYTE, INC. (NASDAQ:VCYT)
Veracyte, Inc. is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. The Company’s commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis, centers on the Afirma Gene Expression Classifier (GEC). The Afirma GEC is offered directly or as part of a solution that also includes cytopathology. The Company operates in the pulmonology diagnostics market. It offers Percepta Bronchial Genomic Classifier, a genomic test to resolve ambiguity in lung cancer diagnosis. It also offers the Envisia Genomic Classifier, which is designed to help in the assessment of patients suspected to have idiopathic pulmonary fibrosis.